Vimarsana
Biggest News Aggregation in the World

Page 2 - Sumatriptan Injection News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sumatriptan Injection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sumatriptan Injection Today - Breaking & Trending Today

Lipocine And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO® - Vimarsana News

Lipocine And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO®

/PRNewswire/ -- Under the terms of Agreement Lipocine to receive: Up to $21.0 million in licensing fees, including $11.0 million payable immediately and $10.0...

Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial - Vimarsana News

Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial

Published: May 06, 2021 EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc.. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests. Mr. Renda has had a successful career in leading commercial sales, marketing, and operations at large and mid-sized pharmaceutical companies. Prior to joining Antares, Mr. Renda was Vice President, U.S. Sales Autoimmune and Rare Disease at Mallinckrodt Pharmaceuticals...

Antares Pharma Appoints Joseph Renda as Senior Vice - Vimarsana News

Antares Pharma Appoints Joseph Renda as Senior Vice

Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial May 06, 2021 07:15 ET | Source: Antares Pharma, Inc. Antares Pharma, Inc. Ewing, New Jersey, UNITED STATES EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests. Mr. Renda has had a successful career in leading commercial sales, m...

Antares Pharma Appoints Dr. Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer - Vimarsana News

Antares Pharma Appoints Dr. Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer

Antares Pharma Appoints Dr. Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer April 26, 2021 08:30 ET | Source: Antares Pharma, Inc. Antares Pharma, Inc. Ewing, New Jersey, UNITED STATES EWING, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Peter Richardson, MRCP, as Executive Vice President, Research and Development and Chief Medical Officer. In this role, Dr. Richardson will over...

Antares Pharma to Report First Quarter 2021 Financial and Operating Results - Vimarsana News

Antares Pharma to Report First Quarter 2021 Financial and Operating Results

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Antares Pharma to Report First Quarter 2021 Financial and Operating Results Antares Pharma, Inc.April 27, 2021 GMT EWING, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced it will release its first quarter 2021 financial and operating results on Thursday, May 6, 2021, before the market opens. Antares will host a conference call on Thursday, May 6, 2021 at 8:30am ET to discuss the results. The dia...

Source: apnews.com